<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R Rudnick, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ihab Wahba, MD, FACP, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dana Miskulin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1765798330"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nephrogenic systemic fibrosis (NSF) is a disorder seen only in patients with advanced kidney disease and is characterized by two primary features [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Thickening and hardening of the skin overlying the extremities and trunk</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marked expansion and fibrosis of the dermis in association with CD34+ fibrocytes</p><p></p><p>NSF was originally named nephrogenic fibrosing dermopathy (NFD) because of the characteristic skin findings. However, subsequent studies showed that some patients had fibrosis of deeper structures, including muscle, fascia, lungs, and heart [<a href="#rid1">1</a>]. Because of the systemic findings, NSF is preferred to NFD [<a href="#rid4">4</a>]. (See <a class="local">'Systemic involvement'</a> below.)</p><p>While NSF is only seen among patients with kidney disease, retention of gadolinium (Gd) has been demonstrated in other organs (eg, brain) in patients without and with kidney disease [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Concerns about gadolinium retention multiple organs'</a>.)</p><p>This topic will discuss the epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, and treatment of NSF. General principles of magnetic resonance imaging (MRI), indications for Gd use, and patient evaluation prior to Gd administration are discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"</a> and  <a class="medical medical_review" href="/z/d/html/5309.html" rel="external">"Principles of magnetic resonance imaging"</a>.)</p><p class="headingAnchor" id="H3623473408"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The cases of nephrogenic systemic fibrosis (NSF) reported in the beginning of the millennium were attributed to the use of the unstable linear gadolinium-based contrast agents (GBCAs; eg, <a class="drug drug_general" data-topicid="8962" href="/z/d/drug information/8962.html" rel="external">gadodiamide</a>, gadopentetate, or <a class="drug drug_general" data-topicid="8965" href="/z/d/drug information/8965.html" rel="external">gadoversetamide</a>) administered to patients with dialysis-dependent end-stage kidney disease (ESKD) or acute kidney injury (AKI) [<a href="#rid3">3,6,7</a>]. The linear and macrocyclic GBCAs (eg, gadobenate, gadoterate, or <a class="drug drug_general" data-topicid="8886" href="/z/d/drug information/8886.html" rel="external">gadoteridol</a>) are more stable as a result of higher thermodynamic stability and low kinetic inertness, both of which minimize the release of the pathogenic free gadolinium (Gd<sup>3+</sup>) in vivo [<a href="#rid8">8</a>]. Clinician awareness of NSF, adoption of restrictive policies regarding GBCAs for patients with advanced kidney disease, and the use of more stable GBCAs have led to a dramatic reduction in NSF cases after 2007 [<a href="#rid3">3,8-11</a>]. (See <a class="local">'Pathogenesis'</a> below.) </p><p>The American College of Radiology (ACR) has classified the GBCAs into three categories according to their likelihood of causing NSF, with group I being the most likely GBCAs to cause NSF, group II being the least likely to cause it, and group III having limited data suggestive of low risk of NSF  (<a class="graphic graphic_table graphicRef119865" href="/z/d/graphic/119865.html" rel="external">table 1</a>) [<a href="#rid12">12-15</a>]. The details regarding various gadolinium (Gd) groups are discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Gadolinium group and risk for nephrogenic systemic fibrosis'</a>.)</p><p>The incidence rates of NSF are difficult to ascertain, as they vary depending upon the frequency and severity of kidney disease among patients studied, the type and dose of GBCA, and the sample size under study [<a href="#rid16">16-18</a>]. The risk of NSF with the use of more stable linear or macrocyclic GBCAs is substantially lower than with older, unstable agents, but is not zero:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group I agents</strong> – In one representative study with estimates of NSF presented by chronic kidney disease (CKD) stage, NSF incidence after receipt of <a class="drug drug_general" data-topicid="8962" href="/z/d/drug information/8962.html" rel="external">gadodiamide</a> (a group I agent) was 0.4 percent among patients with ESKD on maintenance hemodialysis, 0.6 percent among patients with CKD and estimated glomerular filtration rate (eGFR) 15 to 30 mL/min/1.73 m<sup>2</sup>, 10 percent with CKD and eGFR &lt;5 mL/min/1.73 m<sup>2 </sup>not on dialysis, and 20 percent among patients with AKI and rising serum creatinine at the time of exposure [<a href="#rid18">18</a>]. Other studies also highlight the risk with group I agents [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group II agents</strong> – Multiple studies have reported that the risk of NSF is substantially lower with group II agents [<a href="#rid6">6-8,11,14,19-31</a>]. Although these studies essentially reported no cases of NSF, they were limited by low numbers of patients with an eGFR &lt;15 mL/min/1.73 m<sup>2</sup> or who were on dialysis, and for the most part, patients received only one to two exposures of GBCA at a standard dose [<a href="#rid8">8</a>]. Most cases of NSF after group II agents are confounded (ie, a group I agent was administered prior to a group II agent, although the timing between administrations varied, and administration of the group II agent was more temporally related to the NSF); a minority of cases (single digit) were unconfounded (ie, only a group II agent was administered). Representative studies are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of 16 prospective and retrospective studies including 4931 patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> who were administered group II agents, there were no unconfounded cases of NSF identified [<a href="#rid11">11,31</a>]. The number of confounded cases was not reported, and patients with AKI were not included.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a large analysis of NSF cases from 2006 to 2016, 25 confounded cases and five unconfounded cases of NSF (three of which were biopsy confirmed) were identified [<a href="#rid6">6</a>]. Of these, there were three confirmed unconfounded cases. However, the proportion of patients with advanced CKD or AKI who received <a class="drug drug_general" data-topicid="8632" href="/z/d/drug information/8632.html" rel="external">gadobutrol</a> was not reported, and, therefore, the incidence of NSF among patients with advanced kidney disease after administration of a group II GBCA was unclear. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group III agents</strong> – Data on group III agents are limited, and therefore their safety cannot be ascertained with as much certainty as for the group II agents. However, no unconfounded cases of NSF have been reported among patients with CKD to date [<a href="#rid14">14,15,32-34</a>].</p><p></p><p>There appears to be no predilection to NSF by sex, race, age, etiology or duration of kidney disease, or time on dialysis [<a href="#rid35">35-39</a>]. Conversely, NSF may be more common in peritoneal dialysis as compared with hemodialysis [<a href="#rid40">40,41</a>]. Additional discussion regarding patient-level risk factors is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patient risk factors for nephrogenic systemic fibrosis'</a>.) </p><p>A number of other possible associations with NSF have been found or suggested in patients with kidney disease, including vascular manipulation, increased vascular permeability, presence of edema, infection, medications (including erythropoietin), hyperphosphatemia, and liver transplantation [<a href="#rid3">3,38,40-48</a>]. However, it is difficult to ascertain these associations.</p><p class="headingAnchor" id="H1480660671"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Gadolinium-containing contrast agents (GBCAs) have been implicated as a cause for nephrogenic systemic fibrosis (NSF) [<a href="#rid41">41,49-55</a>]. A discussion of the various types/groups of gadolinium (Gd) and their varying risk for NSF are discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Gadolinium group and risk for nephrogenic systemic fibrosis'</a>.)</p><p>Free gadolinium (Gd<sup>3+</sup>) is a poorly soluble and highly toxic lanthanide heavy metal [<a href="#rid50">50</a>]. In order to enable its use in humans, Gd<sup>3+</sup> is bound to a large organic molecule called a chelate. Gd<sup>3+</sup> may dissociate from the chelate with continued in vivo exposure, such as in patients with end-stage kidney disease (ESKD) before undergoing high-efficiency dialysis. Such dissociation from the chelate has been shown to be enhanced in the presence of iron [<a href="#rid56">56</a>].</p><p>Gd<sup>3+</sup> has several deleterious effects in vivo [<a href="#rid50">50</a>]. It is similar in size to calcium, which allows it to bind calcium-binding enzymes, thereby inhibiting them. It precipitates in tissues, disrupts calcium ion passage in nerve and muscle cells, and interferes with intracellular enzymes and cell membranes. Gd<sup>3+ </sup>can also form precipitates with certain anions (such as phosphate) that are elevated in patients with kidney disease [<a href="#rid4">4,57</a>].</p><p>How Gd<sup>3+</sup> or its precipitates lead to NSF is poorly understood [<a href="#rid4">4,58</a>]. The tissues affected by NSF resemble tissues that are undergoing an injury reaction. Similar to injured tissue, the tissues affected by NSF contain a higher number of macrophages and fibroblasts. It is postulated that the fibrogenic cytokines secreted by the macrophages and fibroblasts lead to a cascade of events similar to wound healing, but with exaggerated fibrosis.</p><p>Three proposed mechanisms of exaggerated fibrogenic response are [<a href="#rid50">50,51,59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activation</strong> <strong>of the transforming growth factor</strong> <strong>(TGF)</strong> <strong>beta-1 pathway</strong> – There is a marked increase in TGF-beta-1 messenger RNA levels along with the presence of many CD68+/factor XIIIa+ dendritic cells in the skin and fascia of affected patients [<a href="#rid60">60,61</a>]. According to one theory, a noxious stimulus activates CD68+/factor XIIIa+ dendritic cells in tissue, which then produce TGF-beta-1 [<a href="#rid35">35</a>]. However, TGF-beta-1 itself regulates dendritic cell maturation and antigen presentation. A vicious cycle ensues as this leads to further recruitment and activation of dendritic cells and more TGF-beta-1 production, ultimately resulting in tissue fibrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increase in circulating fibrocytes </strong>–<strong> </strong>A second theory is that Gd deposition in skin in some manner, possibly as a direct toxin, stimulates the bone marrow to produce CD34+ circulating fibroblasts, which accumulate in the affected tissue and produce collagen, even in the absence of tissue injury [<a href="#rid35">35,59</a>]. This is supported by one study showing that tissue fibrosis in NSF is caused by fibrocytes recruited from the circulation rather than by proliferation of resident dendritic cells [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secretion of cytokines and growth factors by monocytes </strong>– Peripheral blood monocytes are thought to secrete proinflammatory and profibrotic cytokines as well as growth factors in response to Gd chelates [<a href="#rid62">62</a>]. Cytokines secreted include interleukin (IL) 13, IL-4, and IL-6, and growth factors include TGF-beta and vascular endothelial growth factor, which are all specific to a monocyte response.</p><p></p><p class="headingAnchor" id="H3658545331"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Nephrogenic systemic fibrosis (NSF) is characterized by skin involvement in all patients and systemic involvement in some [<a href="#rid1">1</a>]. The median onset of NSF after gadolinium (Gd) exposure is 42 days, with an interquartile range of 19 to 90 days [<a href="#rid3">3</a>]. Disease has been detected anywhere from 1 day to 10 years after exposure. </p><p class="headingAnchor" id="H1489362856"><span class="h2">Skin involvement</span><span class="headingEndMark"> — </span>Skin disease in NSF typically presents as fibrotic, indurated papules, plaques, or subcutaneous nodules that may or may not be erythematous [<a href="#rid1">1,61,63</a>].</p><p>In the majority of cases, the disease is bilateral and symmetric. The skin lesions first appear on the ankles, lower legs, feet, and hands, and then progress proximally to involve the thighs, forearms, and, infrequently, the buttocks [<a href="#rid35">35,37</a>]. Unusual distribution patterns involving the skin overlying the middle [<a href="#rid64">64</a>] and lower abdomen [<a href="#rid35">35,37</a>] have been reported. The head (other than scleral plaques) is usually spared [<a href="#rid35">35,65</a>].</p><p>The lesions are often preceded by edema of the region, often mimicking cellulitis. Upon resolution of edema, the involved skin retains a thickened and indurated texture [<a href="#rid1">1</a>]. The skin may have a "cobblestone" [<a href="#rid66">66</a>], "woody" [<a href="#rid1">1,35,60</a>], or <em>peau d'orange</em> appearance (orange peel-like)  (<a class="graphic graphic_picture graphicRef77008" href="/z/d/graphic/77008.html" rel="external">picture 1</a>) [<a href="#rid1">1,65</a>]. The lesions may be pruritic or present with sharp pain or a burning sensation [<a href="#rid1">1,36,60</a>]. Confluent dermal plaques with thickening and hardening may also occur. </p><p>There may be sclerodactyly or loss of skin folds over the dorsum of the hands and lower extremities [<a href="#rid60">60</a>]. Unlike autoimmune sclerosing conditions, livedo reticularis is not a feature of NSF. Late in the disease, hyperpigmentation, hairlessness, and epidermal atrophy have been described [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H3127798644"><span class="h2">Systemic involvement</span><span class="headingEndMark"> — </span>The prevalence of systemic involvement is unknown, but a number of different organ system manifestations have been described:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle and joint involvement </strong>– Bilateral flexion joint contractures can occur in up to 70 percent of patients with advanced disease [<a href="#rid3">3,35,60,68,69</a>]. The limitations in range of motion and flexibility are commonly due to periarticular skin thickening and fibrosis, since there is no evidence of joint damage in the form of synovitis or arthritis  (<a class="graphic graphic_picture graphicRef69935 graphicRef82710" href="/z/d/graphic/69935.html" rel="external">picture 2A-B</a>). Muscle induration may be seen [<a href="#rid37">37,68,70</a>], but strength is normal or only slightly reduced [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Internal organs </strong>– Fibrosis has also been identified in a variety of internal organs, including the lungs (with reduced diffusion capacity) [<a href="#rid60">60</a>] and diaphragm (with respiratory failure) [<a href="#rid37">37,71</a>], myocardium [<a href="#rid37">37,60,72</a>], pericardium, pleura [<a href="#rid37">37</a>], and dura mater [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scleral plaques in young patients </strong>– Yellow asymptomatic scleral plaques are common among patients with NSF  (<a class="graphic graphic_picture graphicRef54337" href="/z/d/graphic/54337.html" rel="external">picture 3</a>) [<a href="#rid1">1,38</a>]. However, these can also be seen with aging in the general population. Thus, scleral plaques are considered significant if noted in patients younger than 45 years of age.</p><p></p><p class="headingAnchor" id="H3960435636"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of nephrogenic systemic fibrosis (NSF) is based upon histopathologic examination of biopsy tissue from an involved site in a patient with classic clinical findings.</p><p class="headingAnchor" id="H469403592"><span class="h2">When to suspect NSF</span><span class="headingEndMark"> — </span>We suspect NSF in patients with kidney disease and history of gadolinium (Gd) exposure who present with classic skin and joint findings. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>Laboratory findings are generally nonspecific. Concomitant presence of restrictive lung disease, myocardial fibrosis, cardiomyopathy, or fibrosis of the fascia and muscles on various imaging studies in someone with classic skin findings may suggest the diagnosis [<a href="#rid35">35,68</a>].</p><p class="headingAnchor" id="H1317228797"><span class="h2">Confirmation of diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of NSF can be confirmed by combining clinical findings and histopathology [<a href="#rid69">69</a>]. Thus, in patients whose clinical picture is suspicious for NSF, we obtain a deep incisional or a punch biopsy to capture tissue from subcutaneous fat, fascia, and muscle [<a href="#rid1">1,38,63</a>].</p><p>The findings obtained from physical examination and histopathologic evaluation of the skin biopsy are then used to calculate clinical and histologic scores using a system developed from the Yale International NSF Registry  (<a class="graphic graphic_table graphicRef64487" href="/z/d/graphic/64487.html" rel="external">table 2</a>) [<a href="#rid69">69</a>]. Clinical and histologic scores are plotted to establish the diagnosis of NSF  (<a class="graphic graphic_figure graphicRef55350" href="/z/d/graphic/55350.html" rel="external">figure 1</a>). Clinical examination and/or biopsy should be repeated in patients with inconsistent or suggestive findings  (<a class="graphic graphic_figure graphicRef55350" href="/z/d/graphic/55350.html" rel="external">figure 1</a>). The utility of this scoring system in establishing the diagnosis has not been validated.</p><p>Light microscopy findings can vary with disease severity, ranging from a subtle proliferation of spindle-shaped dermal fibrocytes to a thickened fibrosed dermis with long dendritic processes [<a href="#rid52">52</a>]. There may be an abundance of histiocytes and stellate dendritic cells  (<a class="graphic graphic_picture graphicRef63319 graphicRef75055" href="/z/d/graphic/63319.html" rel="external">picture 4A-B</a>) [<a href="#rid1">1,61</a>]. Thick collagen bundles with surrounding clefts are a prominent finding. Inflammation is usually absent, and elastic fibers are preserved. Osseous sclerotic bodies in skin biopsies obtained from hyperpigmented skin lesions years after the development of NSF have been described. These appear as intensely pink or intensely blue ovoid lesions when stained with hematoxylin and eosin or trichrome stain, respectively. They have been shown to contain gadolinium [<a href="#rid73">73,74</a>].</p><p>Immunohistochemical staining reveals abundant CD34+ dermal dendritic cells, with the dendritic processes aligning along elastic fibers and around collagen bundles, forming a dense network  (<a class="graphic graphic_picture graphicRef76644 graphicRef56673" href="/z/d/graphic/76644.html" rel="external">picture 5A-B</a>) [<a href="#rid61">61</a>]. Dendritic cells positive for CD68, factor XIII, or both may be present [<a href="#rid37">37,60</a>].</p><p>Special testing is available for detecting Gd in tissue specimens, although it is of limited utility [<a href="#rid75">75-77</a>]. An isolated presence of Gd in tissues is not diagnostic of NSF. Conversely, the absence of Gd on histopathology does not exclude a diagnosis of NSF.</p><p class="headingAnchor" id="H1078784669"><span class="h2">Reporting obligations</span><span class="headingEndMark"> — </span>Health care providers are encouraged to report cases and include information about prior exposures, treatments offered, and outcome of treatment to the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fweb.archive.org%2Fweb%2F20180307083821%2Fhttp%3A%2F%2Ficnfdr.org%2F&amp;token=Sk%2Fod%2BOA8g1LX3ucj1zwJCJDiLG5stjxgU2dHHBGyBX1krsK%2FfIUUiirez6Q6rhc9ACbYlPbos1JJOh69kGvyA%3D%3D&amp;TOPIC_ID=1955" target="_blank">International NSF Registry</a> [<a href="#rid78">78</a>].</p><p>Similarly, the US Food and Drug Administration (FDA) urges health care providers and patients in the United States to report adverse event information to the FDA via the MedWatch program by phone (1-800-FDA-1088), fax (1-800-FDA-0178), or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program%3Fdclid%3D%25EF%25BF%25BDclid%21%26utm_content%3D163802025%26utm_campaign%3Dbranded_dtc_xii_2022&amp;token=hgKp97gD8d12OTt39R%2Bayp6Jj9dHuhozycGTRJyThm%2FrpdEIlSKrQ7ylR3wJO5xIfUjUCoeHSoZQsCdmxcAOEFRkn2m%2Fv2ajlaBUTRkcIMm6WWue9qq0xnx650dRK35xzMppIekY0I5UmOOCMbarzp44pGNKC1SB0S3VEH1st%2BvFq1b0aAN2vkNR0EJMNdZhRqLuBAqVsWwLl%2BB5ckiqwQ%3D%3D&amp;TOPIC_ID=1955" target="_blank">their website</a>. Affected patients outside the United States should be reported to the appropriate regulatory agency.</p><p class="headingAnchor" id="H4046616543"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The thickening and hardening of the skin overlying the extremities and trunk as seen in nephrogenic systemic fibrosis (NSF) can mimic a variety of other disorders, such as systemic sclerosis (SS; scleroderma), scleromyxedema, eosinophilic fasciitis, and calciphylaxis [<a href="#rid35">35,60,69,79</a>].</p><p>These conditions can be differentiated from NSF based upon clinical or histologic features:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic sclerosis</strong> <strong>(scleroderma)</strong> – SS can be distinguished from NSF by the presence of Raynaud phenomenon and serologic tests suggestive of the disease. SS is characterized by positive antinuclear antibodies and either anticentromere or anti-DNA topoisomerase I (Scl-70) antibodies, which are typically negative in NSF. Additional information regarding diagnosis of scleroderma is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scleromyxedema </strong>– Scleromyxedema shares some clinical and histopathologic features with NSF. However, it can be distinguished by disease involvement of the head and association with a monoclonal gammopathy, usually of immunoglobulin G lambda type [<a href="#rid35">35,65</a>]. (See  <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy", section on 'Scleromyxedema'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic fasciitis </strong>–<strong> </strong>Eosinophilic fasciitis is distinguished from NSF by sparing of the hands and feet and by presence of eosinophilia and eosinophilic tissue infiltration, which are typically absent in patients with NSF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calciphylaxis </strong>– Calciphylaxis can occur in patients with chronic kidney disease (CKD) and be mistaken for early NSF. However, a tissue biopsy can usually distinguish between these disorders. (See  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>.)</p><p></p><p class="headingAnchor" id="H4094644626"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The best method to prevent nephrogenic systemic fibrosis (NSF) is the avoidance of gadolinium (Gd) in patients with acute kidney injury (AKI) or chronic kidney disease (CKD). If Gd is necessary, then group I agents should be avoided. Patients with AKI or stage 4 or 5 CKD should be informed of the potential risk of NSF associated with gadolinium-based contrast agent (GBCA) administration, the reason GBCA administration is indicated, and whether there are alternative diagnostic studies that would avoid exposure to GBCA while providing comparable information [<a href="#rid15">15</a>].</p><p>Once Gd is administered, hemodialysis may be performed for its removal. However, this practice is controversial and the ability of this post-Gd hemodialysis session to prevent NSF is unproven [<a href="#rid8">8</a>]. (See <a class="local">'Removal of gadolinium with hemodialysis'</a> below.)</p><p class="headingAnchor" id="H2559111751"><span class="h2">Choice of gadolinium product in kidney function impairment</span><span class="headingEndMark"> — </span>The Gd groups and risk for NSF are discussed at length elsewhere  (<a class="graphic graphic_algorithm graphicRef119424" href="/z/d/graphic/119424.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Gadolinium group and risk for nephrogenic systemic fibrosis'</a>.)</p><p class="headingAnchor" id="H2444798562"><span class="h2">Assessment of kidney function prior to gadolinium exposure</span><span class="headingEndMark"> — </span>The decision-making for Gd use by various thresholds of estimated glomerular filtration rate (eGFR) is discussed at length elsewhere  (<a class="graphic graphic_algorithm graphicRef119424" href="/z/d/graphic/119424.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patient risk factors for nephrogenic systemic fibrosis'</a>.)</p><p class="headingAnchor" id="H1788854205"><span class="h2">Removal of gadolinium with hemodialysis</span><span class="headingEndMark"> — </span>No high-quality data demonstrate that hemodialysis may prevent NSF. After inadvertent exposure to Gd or appropriate administration of Gd following a risk-benefit discussion, our approach to hemodialysis is based upon the causative role of group I agents in NSF, lack of absolute certainty over the benign nature of group II and III agents, and the high dialyzability of Gd. However, we acknowledge the uncertainty of clinical benefit with our approach, which is outlined below [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients already on hemodialysis</strong> – Among patients with end-stage kidney disease (ESKD) or AKI who are already receiving hemodialysis, we dialyze as soon as possible (within hours, not days) after Gd is administered [<a href="#rid8">8</a>]. We attempt to schedule the MRI with Gd just before the patient's next scheduled dialysis session, when possible. Otherwise, we perform an additional dialysis treatment shortly after the imaging study. In addition, we perform a second dialysis session approximately 24 hours after the first session.</p><p></p><p class="bulletIndent1">However, other experts take a different approach in this setting. For example, some guidelines do not recommend urgent dialysis in patients whose MRI with a group II or III GBCA cannot be obtained just before a regularly scheduled dialysis session, and do not recommend multiday dialysis solely to remove group II or III agents [<a href="#rid15">15,80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients not already on hemodialysis</strong> – Among patients with CKD, severe AKI, or AKI with rising creatinine who are not already on hemodialysis, and among patients receiving peritoneal dialysis, our practice differs based upon the type of Gd administered (see  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Gadolinium group and risk for nephrogenic systemic fibrosis'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Group II and III agents </strong>– We do not initiate hemodialysis among such patients solely to prevent NSF, regardless of the presence or absence of a functioning access. The rationale is that the risks of placing central venous access and initiating hemodialysis for the first time outweigh the risk of NSF. Although data for group III agents are limited, available studies have reported no NSF cases among patients with CKD. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Group I agents </strong>– If group I agents are administered to patients who have eGFR &lt;15 mL/min/1.73 m<sup>2 </sup>(whether due to CKD or AKI), patients receiving peritoneal dialysis, or patients with AKI and rising serum creatinine at the time of exposure, we perform two hemodialysis sessions 24 hours apart. For such patients, we would place a temporary dialysis catheter for delivery of hemodialysis if they don't already have a functioning hemodialysis access.</p><p></p><p>Although there is no evidence that hemodialysis lowers the risk or severity of NSF, hemodialysis immediately after Gd exposure results in significant removal of the contrast agent.</p><p>GBCAs have a molecular weight between 500 and 1000 daltons, and they are neither protein bound nor lipophilic [<a href="#rid81">81</a>]. Thus, their volume of distribution is primarily limited to the extracellular fluid. Collectively, these physical properties make GBCAs amenable to dialysis. This was demonstrated in a study of 70 hemodialysis patients who underwent GBCA-enhanced MRI, with average rates of Gd removal of 78, 96, and 99 percent in the first, second, and third every-other-day dialysis sessions, respectively [<a href="#rid82">82</a>]. Other data also report effective clearance of Gd with hemodialysis [<a href="#rid83">83,84</a>].</p><p>There are no studies systematically comparing the incidence of NSF among patients who did and did not receive preventative dialysis. In one study of 12 patients who either had AKI or ESKD, group I GBCA-enhanced MRI was associated with development of NSF despite dialysis performed within two days of exposure among 10 of the 12 patients [<a href="#rid85">85</a>]. Some have questioned the benefit of dialysis for prevention of NSF for reasons including lack of evidence of benefit; low likelihood of NSF with group II agents that are commonly in use since the discovery of NSF; logistical challenges of arranging for dialysis; and concern over rapid distribution of GBCAs within tissues after injection, which may render subsequent dialysis futile [<a href="#rid86">86</a>]. Thus, in light of these collective data, we perform preventative hemodialysis following exposure to GBCAs, as a conservative measure, only among patients who are already on regular hemodialysis either for ESKD, severe AKI, or AKI with a rising creatinine. This is based upon the theoretical benefit of preventing NSF with hemodialysis coupled with negligible risk. However, this risk and benefit analysis does not favor placement of a temporary hemodialysis catheter and performance of dialysis among patients not already on hemodialysis.</p><p class="headingAnchor" id="H71087832"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no proven effective medical therapy for nephrogenic systemic fibrosis (NSF). However, recovery of kidney function may lead to stabilization, marked improvement, or resolution of the disease [<a href="#rid35">35</a>]. Several treatments individually and in combination have been evaluated, but none have shown consistent benefit. In addition, due to the rarity of this condition, most studies involve a small number of patients and a limited duration of follow-up.</p><p class="headingAnchor" id="H3491737096"><span class="h2">Initial management in all patients</span><span class="headingEndMark"> — </span>All patients should continue receiving therapies directed toward improving their kidney function, if reversible. We refer patients with NSF who have an irreversible decline in kidney function to be evaluated for a kidney transplant. This practice is based upon data showing stabilization or improvement in NSF among some patients who recover kidney function [<a href="#rid35">35,38,39,58,87</a>]. NSF does not affect the transplant wait time. Details regarding evaluation of a patient for kidney transplant and wait times are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/7333.html" rel="external">"Kidney transplantation in adults: The kidney transplant waiting list in the United States"</a>.)</p><p>We also refer all patients with NSF for intensive physical therapy to prevent or reverse disability related to joint contractures [<a href="#rid65">65,88</a>]. In addition, we ensure that the patients' hands are splinted in a functional position to prevent progressive contractures of their finger joints [<a href="#rid88">88,89</a>].</p><p class="headingAnchor" id="H3312188785"><span class="h2">Additional therapies for skin manifestations</span><span class="headingEndMark"> — </span>We suggest a trial of extracorporeal photopheresis with ultraviolet A (ECP; also called photochemotherapy), which involves extracorporeal exposure of peripheral blood mononuclear cells to photoactivated 8-methoxypsoralen, followed by reinfusion of the treated cells. ECP induces monocyte-derived tumor necrosis factor (TNF)-alpha, which, in turn, suppresses collagen synthesis and enhances collagenase production. The results with ECP have been inconsistent [<a href="#rid66">66,70,90-92</a>], but we favor a trial based on our limited experience [<a href="#rid93">93</a>].</p><p>Alternatively, treatment with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate is also reasonable, though supportive data are limited to case reports. In two patients with NSF, treatment with imatinib appeared to result in improvement in skin findings and a reduction in dermal collagen [<a href="#rid94">94</a>]. Skin findings recurred upon discontinuation of imatinib and subsequently improved after reinitiation of imatinib. In another patient with lung fibrosis attributed to NSF, treatment with imatinib was associated with improvement in pulmonary function [<a href="#rid95">95</a>]. Other studies have similarly demonstrated the antifibrotic effect of imatinib [<a href="#rid96">96,97</a>]. </p><p class="headingAnchor" id="H3790449768"><span class="h2">Experimental therapies not in use</span><span class="headingEndMark"> — </span>A number of other therapies have been described in case reports or small series. Possible efficacy has been noted with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> [<a href="#rid49">49</a>], intravenous <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> [<a href="#rid98">98,99</a>], alefacept [<a href="#rid100">100</a>], and high-dose intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid101">101</a>]. Topical, intralesional, or oral glucocorticoid therapy and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> have generally shown no benefit [<a href="#rid35">35,90</a>].</p><p class="headingAnchor" id="H1778606392"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Nephrogenic systemic fibrosis (NSF) has a chronic and unremitting course in most patients [<a href="#rid3">3,35,38,58,61,102-104</a>]. Recovery of kidney function may lead to stabilization, marked improvement, or resolution of the disease.</p><p>A 2019 review included studies between the years 2000 and 2019 of patients who had been diagnosed with NSF by clinical evaluation and biopsy confirmation [<a href="#rid3">3</a>]. Of the 639 patients included in the study, only four deaths were attributed to NSF. Follow-up data were available in 341 patients, of whom 12 patients were considered cured and 72 patients had partial improvement. Among these 84 patients with improvement in their symptoms, 34 patients had improvement in their kidney function prior to improvement of NSF. </p><p>Studies among patients who undergo kidney transplantation suggest that not all patients who have improvement in kidney function also have improvement in NSF [<a href="#rid3">3,105,106</a>]. In one study, for example, the rate of NSF improvement was the same in patients who received a kidney transplant and in those who remained on dialysis (55 and 50 percent, respectively) [<a href="#rid106">106</a>]. In addition, symptoms of NSF recurred with deterioration of kidney function among patients with a kidney transplant. Thus, a kidney transplant may improve quality of life in some patients with NSF, but does not guarantee complete or sustained improvement [<a href="#rid35">35,106</a>].</p><p class="headingAnchor" id="H1535766491"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen only in patients with advanced kidney disease. NSF is characterized by two primary features (see <a class="local">'Introduction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thickening and hardening of the skin overlying the extremities and trunk</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Marked expansion and fibrosis of the dermis in association with CD34+ fibrocytes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Clinician awareness of NSF, adoption of restrictive policies regarding gadolinium-based contrast agents (GBCAs) for patients with severe kidney disease, and the use of more stable GBCAs have led to a dramatic reduction in NSF cases after 2007. The incidence of NSF is highest with group I agents, and while the risk with group II agents is very low, it likely is not zero. The risk with group III agents is unknown. There appears to be no predilection to NSF by sex, race, age, etiology or duration of kidney disease, or time on dialysis. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – GBCAs have been implicated as a cause for NSF. Free gadolinium (Gd<sup>3+</sup>) is a poorly soluble and highly toxic lanthanide heavy metal that precipitates in tissues and triggers tissue injury with an exaggerated fibrogenic response. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Skin involvement occurs in all patients, while some also have systemic manifestations. The median onset of NSF after gadolinium (Gd) exposure is 42 days, but NSF can be seen up to 10 years after exposure. Skin disease typically presents as fibrotic, indurated papules, plaques, or subcutaneous nodules. The skin may have a "cobblestone," "woody," or <em>peau d'orange</em> appearance (orange peel-like)  (<a class="graphic graphic_picture graphicRef77008" href="/z/d/graphic/77008.html" rel="external">picture 1</a>). The lesions may be pruritic or present with sharp pain or a burning sensation. Manifestations of systemic involvement may include muscle induration, joint contracture, and fibrosis of the lungs, pleura, diaphragm, myocardium, pericardium, and dura mater. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – We suspect NSF in patients with kidney disease and history of Gd exposure who present with classic skin and joint findings. The diagnosis can be confirmed by combining the clinical findings and histopathologic findings from deep incisional or punch biopsy of the involved subcutaneous fat, fascia, and muscle  (<a class="graphic graphic_picture graphicRef63319 graphicRef75055" href="/z/d/graphic/63319.html" rel="external">picture 4A-B</a> and <a class="graphic graphic_picture graphicRef76644 graphicRef56673" href="/z/d/graphic/76644.html" rel="external">picture 5A-B</a>). These findings are then used to calculate clinical and histologic scores using a system developed from the Yale International NSF Registry  (<a class="graphic graphic_table graphicRef64487" href="/z/d/graphic/64487.html" rel="external">table 2</a>). These scores are then plotted in a calculator to establish the diagnosis of NSF  (<a class="graphic graphic_figure graphicRef55350" href="/z/d/graphic/55350.html" rel="external">figure 1</a>). Clinical examination and/or biopsy should be repeated in patients with inconsistent or suggestive findings. The utility of this scoring system in establishing the diagnosis has not been validated. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Although thickening and hardening of the skin overlying the extremities and trunk can simulate a variety of other disorders, such as scleroderma, scleromyxedema, and eosinophilic fasciitis, a history of a temporally associated Gd exposure in the setting of advanced kidney disease is strongly suggestive of NSF. (See <a class="local">'Differential Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The best method to prevent NSF is the avoidance of Gd. If Gd is necessary in a patient with severe kidney disease, then group I agents should be avoided. Once Gd is administered, we perform hemodialysis for its removal in select patients, despite lack of data demonstrating clinical benefit. Our approach to prevention is as follows (see <a class="local">'Prevention'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gadolinium group </strong>– The Gd groups and risk for NSF are discussed at length elsewhere  (<a class="graphic graphic_algorithm graphicRef119424" href="/z/d/graphic/119424.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Gadolinium group and risk for nephrogenic systemic fibrosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney function assessment </strong>– The decision-making for Gd use by various thresholds of estimated glomerular filtration rate (eGFR) is discussed at length elsewhere  (<a class="graphic graphic_algorithm graphicRef119424" href="/z/d/graphic/119424.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patient risk factors for nephrogenic systemic fibrosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodialysis to remove gadolinium </strong>– In patients already receiving hemodialysis (for either end-stage kidney disease [ESKD] or acute kidney injury [AKI]) who have received a GBCA, we suggest hemodialysis for the removal of Gd (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We dialyze as soon as possible (within hours, not days) after Gd is administered. However, this practice is controversial, and its benefits in prevention of NSF are unproven. (See <a class="local">'Removal of gadolinium with hemodialysis'</a> above.)</p><p></p><p class="bulletIndent2">An attempt should be made to schedule the MRI with Gd just before the patient's next scheduled dialysis session. Otherwise, we perform an additional dialysis treatment shortly after the imaging study. In addition, we perform a second dialysis session approximately 24 hours after the first session.</p><p></p><p class="bulletIndent2">Among patients with chronic kidney disease (CKD) or severe AKI who are <strong>not</strong> already on hemodialysis, and among patients receiving peritoneal dialysis, our practice differs based upon the type of Gd administered to the patient:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Group II and III agents </strong>– We do not perform hemodialysis among these patients regardless of the presence or absence of a functioning access. The rationale is that the risks of placing central venous access and initiating hemodialysis for the first time outweigh the risk of NSF in such patients.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Group I agents </strong>– If group I agents are administered to patients who have eGFR &lt;15 mL/min/1.73 m<sup>2 </sup>(whether due to CKD or AKI), patients receiving peritoneal dialysis, or patients with AKI and rising serum creatinine at the time of exposure, we suggest placing hemodialysis access (if not present) and performing hemodialysis to remove Gd (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). As above, we perform two hemodialysis sessions 24 hours apart.</p><p></p><p class="bulletIndent2">Hemodialysis immediately after Gd exposure results in significant removal of the contrast agent. However, there is no evidence that hemodialysis lowers the risk or severity of NSF, despite effective removal of Gd.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There is no proven effective medical therapy for NSF. However, recovery of kidney function may lead to stabilization, marked improvement, or resolution of the disease. All patients should continue receiving therapies directed toward improving their kidney function, if reversible. We refer patients with NSF who have an irreversible decline in kidney function to be evaluated for a kidney transplant. Intensive physical therapy may help prevent or reverse disability related to joint contractures. Other therapies such as extracorporeal photopheresis and <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate have a limited role in treatment of NSF. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – NSF has a chronic and unremitting course in most patients. A small proportion of patients experience improvement. Cure of NSF is rare. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H346557464"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ambreen Gul, MD, and Shawn E Cowper, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614.</a></li><li><a class="nounderline abstract_t">Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242:647.</a></li><li><a class="nounderline abstract_t">Attari H, Cao Y, Elmholdt TR, et al. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology 2019; 292:376.</a></li><li><a class="nounderline abstract_t">Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum 2006; 35:208.</a></li><li><a class="nounderline abstract_t">McDonald RJ, Levine D, Weinreb J, et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018; 289:517.</a></li><li><a class="nounderline abstract_t">Endrikat J, Dohanish S, Schleyer N, et al. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. Invest Radiol 2018; 53:541.</a></li><li><a class="nounderline abstract_t">Schieda N, Blaichman JI, Costa AF, et al. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018; 69:136.</a></li><li><a class="nounderline abstract_t">Rudnick MR, Wahba IM, Leonberg-Yoo AK, et al. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021; 77:517.</a></li><li><a class="nounderline abstract_t">Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260:105.</a></li><li><a class="nounderline abstract_t">Bruce R, Wentland AL, Haemel AK, et al. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol 2016; 51:701.</a></li><li><a class="nounderline abstract_t">Woolen SA, Shankar PR, Gagnier JJ, et al. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020; 180:223.</a></li><li><a class="nounderline abstract_t">Le Fur M, Caravan P. The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 2019; 11:240.</a></li><li class="breakAll">American College of Radiology. ACR manual on contrast media v10.3. Nephrogenic Systemic Fibrosis. https://Www.acr.org/~/media/ACR/documents/PDF/QualitySafety/resources/contrast-manual/Contrast_Media.pdf/#page=88 (Accessed on December 03, 2019).</li><li><a class="nounderline abstract_t">Lauenstein T, Ramirez-Garrido F, Kim YH, et al. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015; 50:416.</a></li><li><a class="nounderline abstract_t">Weinreb JC, Rodby RA, Yee J, et al. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021; 298:28.</a></li><li><a class="nounderline abstract_t">Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2:264.</a></li><li><a class="nounderline abstract_t">Elmholdt TR, Olesen AB, Jørgensen B, et al. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013; 8:e82037.</a></li><li><a class="nounderline abstract_t">Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248:807.</a></li><li><a class="nounderline abstract_t">Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747.</a></li><li><a class="nounderline abstract_t">Amet S, Launay-Vacher V, Clément O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol 2014; 49:109.</a></li><li><a class="nounderline abstract_t">de Kerviler E, Maravilla K, Meder JF, et al. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Invest Radiol 2016; 51:544.</a></li><li><a class="nounderline abstract_t">Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging 2017; 45:988.</a></li><li><a class="nounderline abstract_t">Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2010; 73:357.</a></li><li><a class="nounderline abstract_t">Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019; 29:1922.</a></li><li><a class="nounderline abstract_t">McWilliams RG, Frabizzio JV, De Backer AI, et al. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. J Magn Reson Imaging 2020; 51:607.</a></li><li><a class="nounderline abstract_t">Michaely HJ, Aschauer M, Deutschmann H, et al. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Invest Radiol 2017; 52:55.</a></li><li><a class="nounderline abstract_t">Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR Am J Roentgenol 2015; 205:469.</a></li><li><a class="nounderline abstract_t">Chrysochou C, Power A, Shurrab AE, et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010; 5:484.</a></li><li><a class="nounderline abstract_t">Nandwana SB, Moreno CC, Osipow MT, et al. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Radiology 2015; 276:741.</a></li><li><a class="nounderline abstract_t">Lohani S, Golenbiewski J, Swami A, Halalau A. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Shankar PR, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage. Radiology 2020; 297:447.</a></li><li><a class="nounderline abstract_t">Starekova J, Bruce RJ, Sadowski EA, Reeder SB. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid. Radiology 2020; 297:556.</a></li><li><a class="nounderline abstract_t">Tseng TY, Tseng JH, Huang BS, et al. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging. Abdom Radiol (NY) 2021; 46:3995.</a></li><li><a class="nounderline abstract_t">Gauthier ID, Macleod CA, Sathiadoss P, et al. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment. Abdom Radiol (NY) 2022; 47:1196.</a></li><li><a class="nounderline abstract_t">Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35:238.</a></li><li><a class="nounderline abstract_t">Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004; 351:2219.</a></li><li><a class="nounderline abstract_t">Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46:754.</a></li><li><a class="nounderline abstract_t">Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15:785.</a></li><li><a class="nounderline abstract_t">Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med 2005; 352:1723.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007; 56:137.</a></li><li><a class="nounderline abstract_t">Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008; 51:966.</a></li><li><a class="nounderline abstract_t">Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008; 190:1069.</a></li><li><a class="nounderline abstract_t">Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6:2212.</a></li><li><a class="nounderline abstract_t">Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25:204.</a></li><li><a class="nounderline abstract_t">Chow DS, Bahrami S, Raman SS, et al. Risk of nephrogenic systemic fibrosis in liver transplantation patients. AJR Am J Roentgenol 2011; 197:658.</a></li><li><a class="nounderline abstract_t">Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004; 140:1401.</a></li><li><a class="nounderline abstract_t">Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7:2425.</a></li><li><a class="nounderline abstract_t">Hope TA, High WA, Leboit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 2009; 253:390.</a></li><li><a class="nounderline abstract_t">Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104.</a></li><li><a class="nounderline abstract_t">Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016; 29:365.</a></li><li><a class="nounderline abstract_t">Idée JM, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Crit Rev Toxicol 2014; 44:895.</a></li><li><a class="nounderline abstract_t">Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016; 311:F1.</a></li><li><a class="nounderline abstract_t">Leyba K, Wagner B. Gadolinium-based contrast agents: why nephrologists need to be concerned. Curr Opin Nephrol Hypertens 2019; 28:154.</a></li><li><a class="nounderline abstract_t">Do C, Barnes JL, Tan C, Wagner B. Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 2014; 307:F844.</a></li><li><a class="nounderline abstract_t">Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 214:584.</a></li><li><a class="nounderline abstract_t">Swaminathan S, Horn TD, Pellowski D, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007; 357:720.</a></li><li><a class="nounderline abstract_t">Birka M, Wentker KS, Lusmöller E, et al. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 2015; 87:3321.</a></li><li><a class="nounderline abstract_t">Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003; 114:563.</a></li><li><a class="nounderline abstract_t">Wagner B, Tan C, Barnes JL, et al. Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 2012; 181:1941.</a></li><li><a class="nounderline abstract_t">Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50:2660.</a></li><li><a class="nounderline abstract_t">Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383.</a></li><li><a class="nounderline abstract_t">Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60:1508.</a></li><li><a class="nounderline abstract_t">Edsall LC, English JC 3rd, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004; 31:247.</a></li><li><a class="nounderline abstract_t">Dundová I, Treska V, Simanek V, Michal M. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc 2005; 37:4187.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004; 19:469.</a></li><li><a class="nounderline abstract_t">Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004; 140:1322.</a></li><li><a class="nounderline abstract_t">Bangsgaard N, Marckmann P, Rossen K, Skov L. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145:183.</a></li><li><a class="nounderline abstract_t">Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004; 30:569.</a></li><li><a class="nounderline abstract_t">Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095.</a></li><li><a class="nounderline abstract_t">Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139:903.</a></li><li><a class="nounderline abstract_t">Kucher C, Steere J, Elenitsas R, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006; 54:S31.</a></li><li><a class="nounderline abstract_t">Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130:209.</a></li><li><a class="nounderline abstract_t">Bandino JP, Gathings RM, Hinen HB, et al. Gadolinium Presence Within Cutaneous Sclerotic Bodies Confirmed by Laser Ablation Inductively Coupled Plasma Mass Spectrometry. JAMA Dermatol 2018; 154:105.</a></li><li><a class="nounderline abstract_t">Gordon ER, Trager MH, Adeuyan O, et al. Alone on a collagen island: Unique findings of osseous sclerotic bodies in nephrogenic systemic fibrosis. JAAD Case Rep 2023; 40:117.</a></li><li><a class="nounderline abstract_t">High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21.</a></li><li><a class="nounderline abstract_t">Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27.</a></li><li><a class="nounderline abstract_t">Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008; 3:968.</a></li><li class="breakAll">The International Center for Nephrogenic Fibrosing Dermopathy Research http://www.icnfdr.org (Accessed on February 19, 2014).</li><li><a class="nounderline abstract_t">Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003; 48:55.</a></li><li><a class="nounderline abstract_t">Weinreb JC, Rodby RA, Yee J, et al. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021; 3:142.</a></li><li><a class="nounderline abstract_t">Rodby RA. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 2008; 21:145.</a></li><li><a class="nounderline abstract_t">Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001; 42:339.</a></li><li><a class="nounderline abstract_t">Saitoh T, Hayasaka K, Tanaka Y, et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006; 24:445.</a></li><li><a class="nounderline abstract_t">Gheuens E, Daelemans R, Mesens S. Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis. Invest Radiol 2014; 49:505.</a></li><li><a class="nounderline abstract_t">Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188:586.</a></li><li><a class="nounderline abstract_t">Yee J. Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House. Adv Chronic Kidney Dis 2017; 24:133.</a></li><li><a class="nounderline abstract_t">Cuffy MC, Singh M, Formica R, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011; 26:1099.</a></li><li><a class="nounderline abstract_t">Ramaizel L, Sliwa JA. Rehabilitation in nephrogenic systemic fibrosis. PM R 2009; 1:684.</a></li><li><a class="nounderline abstract_t">Taylor RA, Levine JM, Jimenez SA. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med 2005; 352:1723.</a></li><li><a class="nounderline abstract_t">Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003; 148:563.</a></li><li><a class="nounderline abstract_t">Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005; 20:220.</a></li><li><a class="nounderline abstract_t">Läuchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004; 208:278.</a></li><li><a class="nounderline abstract_t">Wahba IM, White K, Meyer M, Simpson EL. The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy--report of two cases and review of the literature. Nephrol Dial Transplant 2007; 22:631.</a></li><li><a class="nounderline abstract_t">Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58:2543.</a></li><li><a class="nounderline abstract_t">Mansour J, Coleman C, Mendoza F, et al. Nephrogenic systemic fibrosis-related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy. J Scleroderma Relat Disord 2022; 7:NP7.</a></li><li><a class="nounderline abstract_t">Chandran S, Petersen J, Jacobs C, et al. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009; 53:129.</a></li><li><a class="nounderline abstract_t">Elmholdt TR, Buus NH, Ramsing M, Olesen AB. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J Eur Acad Dermatol Venereol 2013; 27:779.</a></li><li><a class="nounderline abstract_t">Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2:258.</a></li><li><a class="nounderline abstract_t">Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009; 53:133.</a></li><li><a class="nounderline abstract_t">Robinson MR, Routhouska SB, Paspulati RM, Korman NJ. Alefacept therapy for nephrogenic systemic fibrosis: a case series. J Drugs Dermatol 2011; 10:922.</a></li><li><a class="nounderline abstract_t">Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 2004; 150:596.</a></li><li><a class="nounderline abstract_t">Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359.</a></li><li><a class="nounderline abstract_t">Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25:358.</a></li><li><a class="nounderline abstract_t">Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433.</a></li><li><a class="nounderline abstract_t">Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 2008; 22:803.</a></li><li><a class="nounderline abstract_t">Leung N, Shaikh A, Cosio FG, et al. The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant 2010; 10:558.</a></li></ol></div><div id="topicVersionRevision">Topic 1955 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053507" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213364" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31264946" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461067" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30204075" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29547493" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706252" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32861792" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21586680" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885631" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31816007" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30516229" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30516229" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756684" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33170103" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699423" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24349178" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nephrogenic systemic fibrosis in Denmark--a nationwide investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18710976" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of nephrogenic systemic fibrosis at two large medical centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287249" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24169070" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27504794" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27726239" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128909" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30276674" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31287213" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27529464" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26295633" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093350" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875973" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025775" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32808890" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32990511" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33742216" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34997298" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461069" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548783" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183432" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569211" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nephrogenic fibrosing dermopathy: the first 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846862" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Case 35-2004: nephrogenic fibrosing dermopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17318112" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501784" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356457" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nephrogenic systemic fibrosis: possible association with a predisposing infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780542" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775982" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21862808" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Risk of nephrogenic systemic fibrosis in liver transplantation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545556" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17711550" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789237" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431890" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27053146" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25257840" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27147669" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pathophysiology of gadolinium-associated systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531473" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Gadolinium-based contrast agents: why nephrologists need to be concerned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25100280" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Type of MRI contrast, tissue gadolinium, and fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18220317" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699829" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Nephrogenic systemic fibrosis, gadolinium, and iron mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25708271" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753880" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23041060" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334482" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11801769" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nephrogenic fibrosing dermopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19404939" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984577" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387074" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nephrogenic fibrosing dermopathy: a case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736976" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545539" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : UV-A1 phototherapy improves nephrogenic fibrosing dermopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19221265" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nephrogenic systemic fibrosis: late skin manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389718" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21724294" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873886" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nephrogenic fibrosing dermopathy with systemic involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427988" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454565" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117364" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Gadolinium Presence Within Cutaneous Sclerotic Bodies Confirmed by Laser Ablation Inductively Coupled Plasma Mass Spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37766735" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Alone on a collagen island: Unique findings of osseous sclerotic bodies in nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17097388" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109993" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Gadolinium deposition in nephrogenic fibrosing dermopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385397" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385397" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522371" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33604544" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18226002" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11350296" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Safety of gadolinium contrast agent in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16958426" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Dialyzability of gadodiamide in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24619209" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242272" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501073" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079195" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19627963" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rehabilitation in nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15843679" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Case 35-2004: nephrogenic fibrosing dermopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12653751" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Scleromyxoedema-like changes in four renal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15632355" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118390" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17124282" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy--report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668587" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Imatinib mesylate treatment of nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36211205" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nephrogenic systemic fibrosis-related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19012999" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Imatinib in the treatment of nephrogenic systemic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188390" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699422" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022548" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21818517" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Alefacept therapy for nephrogenic systemic fibrosis: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15030351" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885403" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876500" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Nephrogenic fibrosing dermopathy: suspect identified, motive unclear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17907148" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18713261" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055804" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
